Normal view MARC view ISBD view

Variations in normal color vision. III. Unique hues in Indian and United States observers. [electronic resource]

By:

Webster, Michael A

Contributor(s):

Producer: 20021113Description: 1951-62 p. digitalISSN:

1084-7529

Subject(s):

Online resources:

Available from publisher's website

In: Journal of the Optical Society of America. A, Optics, image science, and vision vol. 19

Tags from this library: No tags from this library for this title. Log in to add tags.

Average rating: 0.0 (0 votes)

No physical items for this record

Publication Type: Journal Article; Research Support, U.S. Gov't, P.H.S.

There are no comments on this title.

to post a comment.

Back to results

1 Investigational drugs for the treatment of Zika virus infection: a preclinical and clinical update.
by Han, Yingshan
2 Bictegravir in a fixed-dose tablet with emtricitabine and tenofovir alafenamide for the treatment of HIV infection: pharmacology and clinical implications.
by Pham, Hanh Thi
3 Integrase Strand Transfer Inhibitors in HIV Therapy.
by Mesplède, Thibault
4 Implications for the future of the HIV epidemic if drug resistance against dolutegravir cannot occur in first-line therapy.
by Wainberg, Mark A
5 Will LEDGIN molecules be able to play a role in a cure for HIV infection?
by Mesplède, Thibault
6 The latest evidence for possible HIV-1 curative strategies.
by Pham, Hanh Thi
7 Where are we with injectables against HIV infection and what are the remaining challenges?
by Hassounah, Said A
8 Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence.
by Mesplède, Thibault
9 Is resistance to dolutegravir possible when this drug is used in first-line therapy?
by Mesplède, Thibault
10 What if HIV were unable to develop resistance against a new therapeutic agent?
by Wainberg, Mark A
11 Investigational HIV integrase inhibitors in phase I and phase II clinical trials.
by Han, Yingshan
12 Combination therapies currently under investigation in phase I and phase II clinical trials for HIV-1.
by Pham, Hanh Thi
13 Evolution of HIV integrase resistance mutations.
by Quashie, Peter K
14 Differences among HIV-1 subtypes in drug resistance against integrase inhibitors.
by Han, Ying-Shan
15 Might dolutegravir be part of a functional cure for HIV?
by Wainberg, Mark A
16 The development of novel HIV integrase inhibitors and the problem of drug resistance.
by Wainberg, Mark A
17 Reply to Achieng and Riedel.
by Pham, Hanh Thi
18 HIV Drug Resistance and the Advent of Integrase Inhibitors.
by Quashie, Peter K
19 Effect on HIV-1 viral replication capacity of DTG-resistance mutations in NRTI/NNRTI resistant viruses.
by Pham, Hanh T
20 Resistance to HIV integrase inhibitors.
by Mesplède, Thibault